New Research Reveals Phelan-McDermid Syndrome Is Significantly More Prevalent Than Previously Estimated

A landmark study led by researchers at the Seaver Autism Center for Research and Treatment at Mount Sinai has fundamentally shifted the scientific understanding of Phelan-McDermid syndrome (PMS), a rare genetic disorder that has long remained underdiagnosed. Published in the journal Autism Research, the comprehensive study estimates that the condition affects approximately 1 in 7,300 people. This new figure suggests that the prevalence of PMS is substantially higher than historical estimates, indicating that more than 45,000 individuals in the United States alone may be living with the syndrome—many of whom remain undiagnosed.

Phelan-McDermid syndrome, primarily caused by the deletion or mutation of the SHANK3 gene located on chromosome 22, manifests in a diverse spectrum of clinical challenges. These include global developmental delays, significant intellectual disability, absent or delayed speech, and a variety of behavioral issues. Because the SHANK3 gene plays a critical role in the formation and function of synapses—the communication junctions between neurons—its dysfunction is heavily implicated in neurodevelopmental disorders. Current scientific consensus holds that mutations in SHANK3 may account for as much as one percent of all autism spectrum disorder (ASD) cases, making it one of the most significant single-gene contributors to the autism spectrum.

A Rigorous Methodological Approach to Prevalence

To arrive at these updated figures, the research team at Mount Sinai orchestrated an extensive data-gathering effort, collaborating with prominent genetic testing laboratories, academic medical institutions, and national autism research initiatives. The scale of the study was unprecedented, involving the analysis of genetic testing data from nearly 180,000 individuals diagnosed with autism.

The investigators synthesized information from ten distinct sources, including industry leaders such as GeneDx, Labcorp, and Ambry Genetics, alongside academic powerhouses like the Autism Sequencing Consortium and the SPARK research study. By integrating these massive datasets, the researchers were able to filter out noise and account for significant variables that have historically skewed prevalence data. Specifically, the team adjusted their findings to account for individuals who remain undiagnosed due to limited access to healthcare, the technical constraints of previous generations of genetic testing, and the subset of the PMS population that does not meet the clinical criteria for an autism diagnosis.

The resulting estimate of 13.7 cases per 100,000 individuals represents a critical recalibration of the medical community’s understanding of rare disease epidemiology. This shift underscores the reality that as genetic diagnostic tools become more sophisticated and widely available, the "rare" labels attached to many neurodevelopmental conditions may require periodic, evidence-based updates.

The Diagnostic Bottleneck: Why So Many Go Undiagnosed

The chasm between the estimated 45,000 cases in the United States and the number of currently identified patients highlights a persistent failure in the current healthcare landscape regarding genetic screening. According to Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and lead author of the paper, the issue is multifaceted.

"The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy explained. "Families may also face insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene."

This diagnostic delay is often compounded by the clinical overlap between PMS and other neurodevelopmental conditions. Without specialized chromosomal microarray analysis or whole-exome sequencing, a child might receive a broad diagnosis of autism or global developmental delay without ever uncovering the underlying genetic driver. This creates a missed opportunity for families to access targeted therapies and specialized medical management, which are increasingly tailored to the specific genetic profile of the patient.

Clinical Implications and the Promise of Precision Medicine

The urgency of identifying these patients is no longer solely for the purpose of genetic counseling; it is now a matter of clinical necessity. The landscape of Phelan-McDermid syndrome research has entered a transformative phase, with several pharmaceutical companies and academic labs moving precision medicine approaches into clinical trials.

Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center and senior author of the study, emphasized the shift in the therapeutic paradigm. "We recommend that every child with autism undergo genetic testing, because knowledge is power," Buxbaum stated. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."

The study, which received support from CureSHANK and Neuren Pharmaceuticals, arrives as these therapeutic candidates move through the development pipeline. The goal is to move beyond symptomatic management—treating the seizures, sleep disorders, or behavioral challenges—toward addressing the underlying synaptic dysfunction caused by the SHANK3 deficiency.

An Ethical Imperative for the Medical Community

For advocacy groups, this study serves as a validation of long-held suspicions that the PMS community was far larger than clinical records suggested. Geraldine Bliss, Board Chair of CureSHANK, noted that the data provides a clear mandate for healthcare providers. "This study confirms what many families, clinicians, and advocates have suspected for years," Bliss said. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."

This sentiment is echoed by industry partners who recognize that the success of future drug development depends on clinical trial enrollment. Dr. Rachel Groth, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, characterized the identification of these patients as an "ethical imperative." She noted that patients simply cannot benefit from the impending medical advances if they remain in the shadows of undiagnosed status.

The "Think Genetic First" Movement

The findings of the Mount Sinai study are currently being leveraged to support broader initiatives, such as the "Start Genetic" campaign. This global effort aims to change the clinical workflow for children presenting with developmental delays or autism, encouraging pediatricians and specialists to prioritize genetic testing as a first-line diagnostic step rather than a secondary measure.

The implications for public health policy are profound. If 1 in 7,300 individuals carries this genetic profile, health systems must begin to integrate robust genetic screening into the standard of care for developmental pediatrics. The transition from "clinical observation" to "molecular diagnosis" is not merely an academic exercise; it is the prerequisite for the era of precision medicine.

Looking Ahead: The Future of PMS Research

As clinical trials continue to advance, the focus will likely shift toward the long-term monitoring of patients and the refinement of genetic diagnostic protocols. The Mount Sinai study provides a baseline that will allow researchers to track how diagnosis rates change over the coming decade as access to testing improves.

While the current findings are a significant milestone, they also serve as a reminder of the thousands of families currently navigating the diagnostic odyssey. For these individuals, the study offers a sense of inclusion in a larger community and, perhaps more importantly, the hope that the mechanisms of their children’s conditions are finally being mapped in ways that will lead to meaningful, life-altering treatments.

In summary, the work led by the Seaver Autism Center is more than a statistical update; it is a call to action. By identifying the true prevalence of Phelan-McDermid syndrome, the research provides the empirical foundation necessary to advocate for better insurance coverage, broader clinical guidelines, and a more aggressive approach to genetic medicine. As the medical community digests these findings, the path forward is clear: the integration of genetics into routine care is no longer an optional luxury, but the essential foundation for the future of neurodevelopmental health.